Restari develops medical technologies to restore kidney function and improve diagnostic sampling. Its pipeline includes a late‑stage implantable device that halts and reverses acute kidney injury, a once‑daily oral tablet and a gene‑therapy program aimed at shrinking cysts and correcting the mutation in polycystic kidney disease, and a patented biopsy system that captures larger tissue cores for more accurate pathology.
Funding
Funding not disclosed
Founders
Product
Problem
Acute kidney injury (AKI) and polycystic kidney disease (PKD) currently have limited therapeutic options, leading to permanent kidney damage, dialysis, chronic disease, and high mortality. Additionally, conventional biopsy tools often retrieve insufficient tissue, compromising diagnostic accuracy.
Solution
Restari is developing a portfolio of medical technologies aimed at restoring kidney health and improving diagnostic sampling. For AKI, the company is in late‑stage clinical development of a device designed to halt and reverse injury when it first occurs. For PKD, Restari is creating a once‑daily oral small‑molecule tablet to shrink cysts and slow disease progression, alongside a gene‑therapy program to correct the underlying mutation. The company also offers a patented biopsy device that captures larger tissue specimens, providing clinicians with more material for accurate pathology.
Target Audience
Primary customers are hospitals, nephrology and urology clinics, and research institutions seeking novel therapies for AKI and PKD, as well as pathology labs requiring improved biopsy specimens.
Features
- Implantable or percutaneous AKI device that rapidly restores renal microcirculation and reduces inflammation at the onset of injury
- Oral small‑molecule PKD tablet formulated for once‑daily dosing to reduce cyst size and growth rate
- Gene‑therapy platform targeting the specific genetic mutation responsible for PKD, intended to repair defective genes in renal tissue
- Biopsy system employing proprietary capture technology to obtain larger, higher‑quality tissue cores for enhanced diagnostic confidence
- Integrated pre‑clinical and clinical development pipelines leveraging advanced device engineering, pharmacology, and gene‑editing techniques